Original Article
Upper Extremity Deep Vein Thrombosis: Incidence, Risk Factors, and Effectiveness of Chemoprophylaxis
Abstract
Objectives: Upper extremity deep vein thrombosis (UEDVT) is associated with pulmonary embolism and other complications, but there are no recommendations for UEDVT prophylaxis. The purpose of this study was to establish incidence and risk factors for UEDVT and to determine efficacy of pharmacologic prophylaxis for UEDVT prevention.Methods: For this retrospective cohort study, we identified medical patients aged 18 years and older admitted to 13 Cleveland Clinic hospitals from January 2011 to December 2019. Patients with venous thromboembolism (VTE) on admission, length of stay <1 day, and who received therapeutic anticoagulation were excluded. The potential risk factors included demographics, comorbidities, and medical procedures. Comorbidities were identified via International Classification of Diseases codes, (ICD9 and ICD10), procedures from flowsheets, and prophylaxis from medications administered in the electronic medical record. DVT events were identified by a combination of International Classification of Diseases codes and confirmed by chart review. We performed multivariable logistic regression to identify independent risk factors and the association between VTE prophylaxis and UEDVT. The model’s C statistic was obtained using 1000 bootstrap runs.
Results: Of 194,809 patients, 496 (0.25% of cohort, 36.8% of all VTE) developed UEDVT by 14 days. In the logistic regression model (bias-corrected C statistic 0.87), 11 risk factors predicted UEDVT, the strongest being peripherally inserted central catheter (odds ratio [OR] 4.62, 95% confidence interval [CI] 3.81–5.60) and central venous catheter (OR 3.57, 95% CI 2.91–4.37). The predicted risk among individuals ranged from 0.02% to 23.4%. Prophylaxis was negatively associated with the development of UEDVT (OR 0.72, 95% CI 0.60–0.87).
Conclusions: UEDVT is rare but some patients are high risk. Therefore, UEDVT risk factors should be added to VTE risk assessment models, and patients at high risk for UEDVT should receive chemoprophylaxis.
Posted in: Pulmonary Disease21
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Muñoz FJ, Mismetti P, Poggio R, etal. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008;133:143–148.
2. Khanna R, Maynard G, Sadeghi B, et al. Incidence of hospital-acquired venous thromboembolic codes in medical patients hospitalized in academic medical centers. J Hosp Med 2014;9:221–225.
3. Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019;119:1365–1372.
4. Rokosh RS, Ranganath N, Yau P, et al. High prevalence and mortality associated with upper extremity deep venous thrombosis in hospitalized patients at a tertiary care center. Ann Vasc Surg 2020;65:55–65.
5. Winters JP, Callas PW, Cushman M, et al. Central venous catheters and upper extremity deep vein thrombosis in medical inpatients: the Medical Inpatients and Thrombosis (MITH) study. JThrombHaemost2015;13:2155–2160.
6. Druar NM, Vosburg RW, Cahan M. Obesity increases the risk for upper extremity deep vein thrombosis and pulmonary embolism in patients with upper extremity central venous catheters. Clin Obes 2022;12:e12526.
7. Espitia O, Tissot A, Miossec A, et al. Upper extremity venous thrombosis in hospitalized patients: a prospective epidemiological study. Thromb Res 2024;233:174–180.
8. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e195S–e226S.
9. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2:3198–3225.
10. Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;155:625–632.
11. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8:2450–2457.
12. Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)for medical patients in a tertiary health system. J Am Heart Assoc 2014;3:e001152.
13. Lavau-Denes S, Lacroix P, Maubon A, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol 2013;72: 65–73.
14. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720–728.
15. Cires-Drouet RS, Durham F, Sharma J, et al. Prevalence and clinical outcomes of hospitalized patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2022;10:102–110.
16. Rothberg MB, Hamilton AC, Greene MT, et al. Derivation and validation of a risk factor model to identify medical inpatients at risk for venous thromboembolism. Thromb Haemost 2022;122:1231–1238.
17. Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. NEnglJMed2019;380:1305–1315.
18. Samama MM ,Cohen AT ,Darmon JY ,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. NEngl J Med 1999;341:793–800.
19. Barbar S, Prandoni P. Scoring systems for estimating risk of venous thromboembolism in hospitalized medical patients. Semin Thromb Hemost 2017;43:460–468.
20. Lamontagne F, McIntyre L, DodekP, etal. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study. JAMA Intern Med 2014;174:689–696.
21. Ploton G, Pistorius MA, Raimbeau A, et al. A STROBE cohort study of 755 deep and superficial upper-extremity vein thrombosis. Medicine (Baltimore) 2020;99:e18996.
22. Bahl A, Alsbrooks K, Gala S, et al. Symptomatic deep vein thrombosis associated with peripherally inserted central catheters of different diameters: a systematic review and meta-analysis. Clin Appl Thromb Hemost 2023;29:10760296221144041.
23. Schears GJ, Ferko N, SyedI, et al. Peripherally inserted central catheters inserted with current best practices have low deep vein thrombosis and central line–associated bloodstream infection risk compared with centrally inserted central catheters: a contemporary meta-analysis. J Vasc Access 2021;22:9–25.
24. Eck RJ, Elling T, Sutton AJ, et al. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ 2022;378: e70022.
25. Akl EA, Ramly EP, Kahale LA, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev 2014;2014:CD006468.
26. Bosch FTM, Di Nisio M, Büller HR, et al. Diagnostic and therapeutic management of upper extremity deep vein thrombosis. JClinMed2020;9:1–14.
